1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
67E1D2FB056760DAF00258AEE0048493B
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/establishing-north-america-standards-field-medical-performance-excellence?opendocument
18
19opendocument
203.215.16.238
21
22
23best-in-class.com
24/bestp/domrep.nsf
25BMR




» Products & Services » » Medical Affairs » Field Medical Excellence

Establishing North America Standards for Field Medical Performance Excellence

ID: POP-374


Features:

11 Info Graphics

30 Data Graphics

410+ Metrics

21 Narratives


Pages: 47


Published: 2024


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
Optimizing the performance of field medical teams in the enormous North America market is critical for organizations seeking to maintain a competitive edge globally. Manufacturers must implement effective strategies to streamline operations, optimize engagement with key opinion leaders, and measure performance metrics effectively.

Best Practices, LLC undertook this benchmarking research to provide invaluable insights to field medical leaders, empowering them to navigate challenges and capitalize on opportunities within the North American market. Delvering a wealth of key insights and benchmarks, our report offers a roadmap for optimizing field medical operations in North America.

Leveraging a robust dataset,
the report further provides segmented insights at the country level, offering valuable benchmarks for the United States and Canada.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biopharmaceutical; Manufacturing; Biotech; Consumer Products; Medical Device; Chemical; Clinical Research; Laboratories


Companies Profiled:
Abbott; AbbVie; Alexion Pharmaceuticals; Alkermes; Astellas; AstraZeneca; Bayer; BioMarin; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Clovis Oncology; CSL Behring; Curis; Daiichi Sankyo; Dermavant Sciences; Dompé; Eisai; Eurofarma; Exact Sciences; Galapagos; GE Healthcare; Genentech; Gilead Sciences; GlaxoSmithKline ; Grünenthal; Horizon Therapeutics; Ipsen; Janssen; Jazz Pharmaceuticals; Kyowa Kirin; Lundbeck; Merck; Merck KGaA; Merus; Novartis; Novo Nordisk; OM Pharma; Orchard Therapeutics; Pfizer; Radius Health; Inc.; Sanofi; Seres Therapeutics; Servier; Sunovion; Supernus; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; UCB Pharma; Ultragenyx; Vertex Pharmaceuticals

Study Snapshot

This report provides benchmarks and insights specific to North America. The data from this study is drawn from a larger global pool of field leaders, featuring 448 survey responses from 100+ biopharma manufacturers worldwide. The data is meticulously segmented at the region and country level to provide nuanced insights.

Best Practices, LLC also leveraged its propriety Field Medical Excellence database to provide additional benchmarks tailored to align with diverse portfolio considerations.

Key topics covered in this report include:

  • Effective Field Performance Metrics in North America
  • Field Medical Excellence Framework
  • Target and Engagement Levels of KOLs in North America
  • Average MSL Time Spent in KOL Interactions and on Internal Activities
  • North America Field Medical Staffing Footprint
  • Key Lessons Learned for Measuring MSL Impact in North America

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Average Time in KOL Interactions (minutes per interaction): North American MSLs currently average 32 minutes per interaction. This marks a decline from the 38-minute average observed in 2022.
  • Top-rated Field Metrics: 1) Number of scientific concepts discussed; 2) Number of interactions resulting in a follow-up; and 3) Medical objectives achieved.
Table of Contents

Sr. No.
Topic
Slide No.
I.
Executive Summary: Laying the Foundation for Global Field Medical Performance Standards & ExpectationsPg. 3-17
II.
North America: Region-level benchmarksPg. 18-34
Country-level benchmarksPg. 35-46
III.
About Best Practices, LLCPg. 47

    List of Charts & Exhibits

    I. Executive Summary: Laying the Foundation for Global Field Medical Performance Standards & Expectations

    • Business objectives and research methodology used
    • Regions examined in this benchmark study
    • Participating benchmark companies
    • Global benchmarking findings: Quick takeaways and recommendations
    • Summary of regional data: North America
    • Most effective and utilized field metrics for assessing and demonstrating the value of MSLs
    • Defining “monthly interactions”
    • Distinguishing an "actionable" insight from other kinds of insights
    • Definitions of "actionable insights" from the field
      Crafting a global framework for excellence in field medical engagement
    • Metrics to assess MSL performance in North America
    • Lessons learned around MSL time allocation in field and on external activities

    II. North America

    A. Region-level benchmarks

    • Average number of tiered vs. non-tiered KOLs per MSL in North America
    • Monthly KOL and F2F interactions in North America
    • MSL’s average time spent in each thought leader interaction in North America
    • Weighting criteria for various interaction types on the MSL scorecard – North America
    • Optimal and widely utilized field metrics for assessing and showcasing MSL impact in North America
    • Metrics for engaging non-tiered KOLs in North America
    • Average MSL time in the field (days per year) in North America
    • Percentage of MSL time spent on external, internal and logistics activities in North America
    • Weekly MSL time allocation on each activity stream in North America
    • MSL time in the field vs. on external activities – North America
    • Percentage of overall targets that can be classified as KOLs, HCPs, payers, or other external stakeholders in North America
    • North America field medical staffing footprint
    • Span of control: Number of MSLs per MSL manager in North America
    • Voices from the field: Key lessons learned for measuring MSL impact in North America

    B. Country-level benchmarks

    • Average number of tiered vs. non-tiered KOLs per MSL in United States and Canada
    • Monthly KOL and F2F interactions in United States and Canada
    • MSL’s average time spent in each thought leader interaction in United States and Canada
    • Weighting criteria for various interaction types on the MSL scorecard – United States and Canada
    • Metrics for engaging non-tiered KOLs in United States and Canada
    • Average MSL time in the field (days per year) in United States and Canada
    • Percentage of MSL time spent on external, internal and logistics activities in United States and Canada
    • Weekly MSL time allocation on each activity stream in United States and Canada
    • Percentage of overall targets that can be classified as KOLs, HCPs, payers or other external stakeholders in United States and Canada
    • Average field medical team size – United States and Canada
    • Span of control: Number of MSLs per MSL manager in United States and Canada